MicroPort CardioFlow Medtech Co., Ltd (HKG: 2160), a spin-off of China-based MicroPort Scientific Corp (HKG: 0853), announced the successful completion of the first clinical application of its transcatheter mitral valve replacement (TMVR) system. The procedure demonstrated the system’s safety and efficacy, with postoperative mitral regurgitation resolved and no complications such as paravalvular leakage or left ventricular outflow tract obstruction.
Product Highlights
The TMVR system, the world’s first dry valve product to enter clinical use, features enhanced biocompatibility and anti-calcification properties. It simplifies preoperative preparation, operation, storage, and transportation, improving valve safety and durability. The system supports both transapical and transatrial septal approaches, reducing surgical complexity and risks while offering superior hemodynamic performance.
Clinical Significance
Mitral regurgitation, a common heart valve disease, poses severe risks to patients. MicroPort CardioFlow’s TMVR system addresses this critical need, offering a minimally invasive solution that overcomes challenges in valve anchoring and sealing. The successful first case underscores the system’s potential to transform treatment for mitral valve disorders.-Fineline Info & Tech
